Rani Therapeutics Inc. (RANI)

NASDAQ: RANI · Real-Time Price · USD

1.10

0.03 (2.80%)

At close: May 02, 2025, 3:43 PM

2.80% (1D)

Bid	1.09
Market Cap	63.25M
Revenue (ttm)	1.03M
Net Income (ttm)	-30.02M
EPS (ttm)	-1.05
PE Ratio (ttm)	-1.05
Forward PE	-1.55
Analyst	Buy

Ask	1.11
Volume	172,937
Avg. Volume (20D)	838,250
Open	1.06
Previous Close	1.07
Day's Range	1.05 - 1.11
52-Week Range	1.02 - 7.88
Beta	0.24

About RANI

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-al...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Jul 30, 2021

Employees 105

Stock Exchange NASDAQ

Ticker Symbol RANI

Website https://www.ranitherapeutics.com

Full Company Profile

Analyst Forecast

According to 5 analyst ratings, the average rating for RANI stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 809.75% from the latest price.

Stock Forecasts

Why Price Moved

2 months ago

+14.58%

Rani Therapeutics Holdings shares are trading high... Unlock content with Pro Subscription

2 months ago

+5.11%

Rani Therapeutics Holdings shares are trading higher after the company announced new pharmacokinetic and pharmacodynamic data from a preclinical study evaluating the oral delivery of the glucagon-like peptide-1 receptor agonist semaglutide administered via the RaniPill capsule.

News

1 month ago · seekingalpha.com

Rani Therapeutics Holdings, Inc. (RANI) Q4 2024 Earnings Call Transcript